Pharmaceutical Executive: How are new vaccine technologies impacting the vaccine space? Sylvia Taylor: Vaccine technologies ...
Bexobrutideg leverages targeted protein degradation to eliminate BTK, potentially overcoming resistance mutations and ...
Kardigan’s offering proposes 23.3 million shares at $14–$16, targeting ~$350 million gross proceeds and an implied ~$1.3 ...
While Eli Lilly continues to ride an historic stretch of company growth and performance in the annals of Big Pharma, the now ...
Pharmaceutical Executive spoke with Lisa Bollinger, chief medical officer at Polaryx. The clinical-stage biotech focuses on ...
We have entered a new era, with artificial intelligence (AI) driving one of the fastest technological transformations in ...
Lagoon randomized 724 second-line relapsed SCLC patients 1:1:1 to lurbinectedin, lurbinectedin+irinotecan, or topotecan/irinotecan control, and failed the primary OS endpoint in both investigational ...
FDA’s draft guidance allows sponsors to leverage public and platform knowledge for CMC, nonclinical, and clinical support of ...
Most terminated trials stop for enrollment and funding failures, not negative efficacy or safety, making data-collection cost ...
The ACCESS Model’s significance for the industry is that it introduces a new level of operational capacity to what remains ...
RNA exon editing enables replacement of multiple entire exons at kilobase scale, potentially addressing large genes and high ...
In today's Pharmaceutical Executive Daily, a pharma funding roundup covers two RNA-focused biotechs that secured fresh ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results